Skip to content
Cerevance logo

Cerevance Alternatives & Competitors

12 companies similar to Cerevance — Cerevance a neuroscience company

Companies similar to Cerevance

RogCon, Inc. logo — alternative to Cerevance

RogCon, Inc.

The SCN2A Company

Confluence Pharmaceuticals LLC logo — alternative to Cerevance
PharmaTher Holdings Ltd. (CSE: PHRM) (OTCQB: PHRRF) logo — alternative to Cerevance

PharmaTher Holdings Ltd. (CSE: PHRM) (OTCQB: PHRRF)

PharmaTher is a specialty pharma focused on personalized medicines, specifically peptides...

Reservoir Neuroscience logo — alternative to Cerevance

Reservoir Neuroscience

Developing the world's first therapeutics to heal broken blood vessels in the brain

Rival Readout

Competing with Cerevance? We do this properly.

10 rivals, 90 days of dated moves, ranked by what matters and sourced, in 7 business days.

Book a 7-day Readout
Plex Pharmaceuticals logo — alternative to Cerevance

Plex Pharmaceuticals

Driving pivotal academic breakthroughs into safe and effective treatments for neglected ne...

Autifony Therapeutics logo — alternative to Cerevance

Autifony Therapeutics

Autifony are dedicated to developing new medicines to treat rare genetic CNS disorders

Delix Therapeutics logo — alternative to Cerevance

Delix Therapeutics

Repairing the Brain to Heal the Mind

Myrobalan Therapeutics logo — alternative to Cerevance

Myrobalan Therapeutics

Myro’s mission is to develop first-in-class and best-in-class small molecule drugs for CNS...

Vistagen logo — alternative to Cerevance

Vistagen

Changing the trajectory of mental health care – One Mind at a Time

Praxis Precision Medicines, Inc. logo — alternative to Cerevance

Praxis Precision Medicines, Inc.

The era of genetic neuroscience has arrived

Relmada Therapeutics, Inc logo — alternative to Cerevance

Relmada Therapeutics, Inc

Relmada (Nasdaq: $RLMD) is a clinical-stage company developing novel therapies for the tre...

Cantabio Pharmaceuticals, Inc. logo — alternative to Cerevance

Cantabio Pharmaceuticals, Inc.

Cantabio aim to slow, stop and even prevent the onset & progression of neurodegenerative d...

About Cerevance

Cerevance is a biotechnology startup that was founded in 2016 and is based in the United States. The company recently secured a substantial $47.00M Series B investment on 25 April 2024. The investors in this round included GV, Lightstone Ventures, Agent Capital, Bioluminescence Ventures, DermBiont, Inc., MQB Partners,...

Business keywords

Neuroscience, Pharmaceuticals, Mental Health, Drug Discovery, Neurological Disorders, Brain Research, Psychiatric Diseases, Biopharmaceuticals, Genomics, Neurodegenerative Diseases

Frequently Asked Questions

Companies similar to Cerevance include RogCon, Inc., Confluence Pharmaceuticals LLC, PharmaTher Holdings Ltd. (CSE: PHRM) (OTCQB: PHRRF), Reservoir Neuroscience, Plex Pharmaceuticals. They work in Biotechnology and Pharmaceutical and share Cerevance's focus on neurological disorders, neuroscience and drug discovery.
Bounce Watch lists 12 companies that share Cerevance's industries and are closest to it in business tags, services, target customers, business model and size.
Cerevance is a biotechnology startup that was founded in 2016 and is based in the United States. The company recently secured a substantial $47.00M Series B investment on 25 April 2024. The investors in this round included GV, Lightstone Ventures, Agent Capital, Bioluminescence Ventures, DermBiont, Inc., MQB Partners,...

From the desk

Mapping a market? Start with a Rival Readout.

In 7 business days we read 10 rivals around Cerevance: 90 days of dated moves, ranked by what matters to you, each with its source. Fully credited if you continue.

Compiled from the BounceWatch company index. We last looked at Cerevance on 9 Jun 2026. The 12 companies listed here were last checked between 11 Sep 2024 and 9 Jun 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout